Tech Company Financing Transactions
Georgiamune Funding Round
Georgiamune, based in Gaithersburg, secured $75 million from General Catalyst Partners, Parker Institute for Cancer Immunotherapy and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
8/9/2023
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series A
Investors
Proceeds Purpose
The company will initiate a first-in-human, open-label, phase 1/2 dose-escalation with enrichment and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and antitumor activity of GIM-122 as a single agent in adults with advanced solid malignancies who have failed treatment with a checkpoint inhibitor.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
942 Clopper Rd
Gaithersburg, MD 20878
USA
Gaithersburg, MD 20878
USA
Phone
Undisclosed
Website
Email Address
Overview
Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Samir Khleif
Chief Medical Officer
Sonia Quaratino
Browse more venture capital transactions:
Prev: 8/9/2023: ADARx Pharmaceuticals venture capital transaction
Next: 8/9/2023: Stabl Energy venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. All VC database entries on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs